Interaction of opiates with opioid binding sites in the bovine adrenal medulla: I. Interaction with delta and mu sites.
In the present study we examined the interaction of opiates with the delta and mu opioid binding sites in the bovine adrenal medulla. [3H][D-Ala2, D-Leu5]-enkephalin ( [3H]DADLE) in the presence of saturating concentrations of morphiceptin was used to analyze delta site interactions, whereas either [3H]DADLE in the presence of saturation concentrations of [D-Ser2, Leu5]-enkephalin-Thr6 (DSLET) or [3H][D-Ala2, Me-Phe4, Gly5-ol]-enkephalin ( [3H]DAGO) was used for the determination of mu sites. Both binding sites were found to interact stereoselectively with opiates. The binding was affected differentially by proteolytic enzymes (trypsin, alpha-chymotrypsin, pepsin), N-ethylmaleimide, and A2-phospholipase. Kinetic and equilibrium binding studies revealed that in each case radiolabeled opiates interact with one class of binding sites, following simple second-order bimolecular kinetics. Competition for binding by opiates and opioid peptides confirmed the delta and mu selectivity of these sites. Monovalent (Na+, Li+, K+) and divalent (Mg2+, Mn2+, Ca2+) ions interacted differentially with these two binding sites: In general, monovalent cations affected preferentially the apparent number of binding sites, whereas divalent ions modified the equilibrium dissociation constant. Furthermore, positive or negative cooperativity and an apparent heterogeneity of binding sites were detected under some ionic conditions.
Castanas
E
E
Bourhim
N
N
Giraud
P
P
Boudouresque
F
F
Cantau
P
P
Oliver
C
C
D000313:Adrenal Medulla / Q000378:metabolism*; D000818:Animals; D001665:Binding Sites; D002417:Cattle; D002586:Cesium / Q000494:pharmacology; D002712:Chlorides; D004723:Endorphins / Q000378:metabolism; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004743:Enkephalin, Leucine / Q000031:analogs & derivatives / Q000378:metabolism; D016308:Enkephalin, Leucine-2-Alanine; D004744:Enkephalin, Methionine / Q000378:metabolism; D004745:Enkephalins / Q000378:metabolism; D005033:Ethylmaleimide / Q000494:pharmacology; D007700:Kinetics; D008094:Lithium / Q000494:pharmacology; D009294:Narcotics / Q000378:metabolism*; D009842:Oligopeptides / Q000378:metabolism; D010741:Phospholipases A / Q000494:pharmacology; D011188:Potassium / Q000494:pharmacology; D011957:Receptors, Opioid / Q000187:drug effects / Q000378:metabolism*; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; D012964:Sodium / Q000494:pharmacology; D013237:Stereoisomerism
D002712:Chlorides; D004723:Endorphins; D004745:Enkephalins; D009294:Narcotics; D009842:Oligopeptides; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D002586:Cesium; D004744:Enkephalin, Methionine; D004743:Enkephalin, Leucine; D016308:Enkephalin, Leucine-2-Alanine; C034318:enkephalin, Ser(2), Leu(5), Thr(6)-; C028889:morphiceptin; D008094:Lithium; D012964:Sodium; D010741:Phospholipases A; C028019:cesium chloride; D005033:Ethylmaleimide; D011188:Potassium